1
|
Coriat P, Richer C, Douraki T, Gomez C, Hendricks K, Giudicelli JF, Viars P. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology 1994; 81:299-307. [PMID: 8053578 DOI: 10.1097/00000542-199408000-00006] [Citation(s) in RCA: 187] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
BACKGROUND Several cases of hypotension have been reported in patients who received angiotensin-converting enzyme inhibitors (ACEIs) before a surgical procedure, suggesting that interactions between ACEIs and anesthesia may be neither beneficial nor predictable. To determine if continuation of ACEI therapy until the morning of surgery leads to an unacceptable decrease in blood pressure on induction, we investigated 51 vascular surgical patients that were chronically treated for hypertension with either captopril or enalapril. METHODS After randomization, ACEI therapy was either continued until the morning of surgery or stopped at the time of the preanesthetic visit, at least 12 h (captopril) or 24 h (enalapril) before surgery. Each patient received a standardized anesthetic induction. If systolic blood pressure (monitored using a radial artery cannula) decreased to less than 90 mmHg in response to induction, ephedrine was administered. RESULTS A marked decrease in plasma converting-enzyme activity was found in patients who received enalapril until the morning of the surgical procedure, and 100% of them required ephedrine after induction. In patients who received their usual dose of captopril on the morning of surgery, plasma converting-enzyme activity was reduced to a lesser extent (when compared with patients who received enalapril). Finally, in the patients in whom ACEI therapy, either enalapril or captopril, was stopped of the evening before surgery, the incidence of induction-induced hypotension was significantly less when enalapril or captopril therapy has been discontinued. CONCLUSIONS These data indicate that in hypertensive patients chronically treated with ACEIs, maintenance of therapy until the day of surgery may increase the probability of hypotension at induction.
Collapse
|
Clinical Trial |
31 |
187 |
2
|
Kripalani KJ, McKinstry DN, Singhvi SM, Willard DA, Vukovich RA, Migdalof BH. Disposition of captopril in normal subjects. Clin Pharmacol Ther 1980; 27:636-41. [PMID: 6989546 DOI: 10.1038/clpt.1980.90] [Citation(s) in RCA: 131] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The disposition of captopril, an angiotensin-converting enzyme inhibitor with antihypertensive properties, was studied in 10 normal male subjects after a single 100-mg tablet of 35S-labeled drug. Average absorption parameters for unchanged captopril in blood were Tmax 0.93 +/- 0.08 hr and Cmax 800 +/- 76 ng/ml. For total radioactivity in blood the values were Tmax 1.05 +/- 0.08 hr and Cmax 1,580 +/- 90 ng/ml (as captopril equivalents). Because of the curvilinearity of the semilogarithmic plots of blood concentrations of captopril:time, elimination half-life (t1/2) of unchanged drug could not be determined. At 1 hr unchanged captopril accounted for about 52% of total radioactivity in blood, and the dimeric disulfide metabolite of captopril accounted for about 10%. In the first 5 days after dosing, an average of about 68% of the radioactive dose was recovered in urine and 18% in feces. The distribution of radioactivity in the first 24-hr urine sample (66% of the dose) was 58% captopril (38% of dose), 2% captopril disulfide (1.5% of dose), and 40% unidentified polar metabolites (26% of dose).
Collapse
|
|
45 |
131 |
3
|
van Kats JP, Duncker DJ, Haitsma DB, Schuijt MP, Niebuur R, Stubenitsky R, Boomsma F, Schalekamp MA, Verdouw PD, Danser AH. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation 2000; 102:1556-63. [PMID: 11004147 DOI: 10.1161/01.cir.102.13.1556] [Citation(s) in RCA: 88] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND The mechanisms behind the beneficial effects of renin-angiotensin system blockade after myocardial infarction (MI) are not fully elucidated but may include interference with tissue angiotensin II (Ang II). METHODS AND RESULTS Forty-nine pigs underwent coronary artery ligation or sham operation and were studied up to 6 weeks. To determine coronary angiotensin I (Ang I) to Ang II conversion and to distinguish plasma-derived Ang II from locally synthesized Ang II, (125)I-labeled and endogenous Ang I and II were measured in plasma and in infarcted and noninfarcted left ventricle (LV) during (125)I-Ang I infusion. Ang II type 1 (AT(1)) receptor-mediated uptake of circulating (125)I-Ang II was increased at 1 and 3 weeks in noninfarcted LV, and this uptake was the main cause of the transient elevation in Ang II levels in the noninfarcted LV at 1 week. Ang II levels and AT(1) receptor-mediated uptake of circulating Ang II were reduced in the infarct area at all time points. Coronary Ang I to Ang II conversion was unaffected by MI. Captopril and the AT(1) receptor antagonist eprosartan attenuated postinfarct remodeling, although both drugs increased cardiac Ang II production. Captopril blocked coronary conversion by >80% and normalized Ang II uptake in the noninfarcted LV. Eprosartan did not affect coronary conversion and blocked cardiac Ang II uptake by >90%. CONCLUSIONS Both circulating and locally generated Ang II contribute to remodeling after MI. The rise in tissue Ang II production during angiotensin-converting enzyme inhibition and AT(1) receptor blockade suggests that the antihypertrophic effects of these drugs result not only from diminished AT(1) receptor stimulation but also from increased stimulation of growth-inhibitory Ang II type 2 receptors.
Collapse
|
|
25 |
88 |
4
|
Huang T, He Z, Yang B, Shao L, Zheng X, Duan G. Simultaneous determination of captopril and hydrochlorothiazide in human plasma by reverse-phase HPLC from linear gradient elution. J Pharm Biomed Anal 2006; 41:644-8. [PMID: 16413728 DOI: 10.1016/j.jpba.2005.12.007] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2005] [Revised: 12/02/2005] [Accepted: 12/05/2005] [Indexed: 11/26/2022]
Abstract
A simple, rapid and sensitive high-performance liquid chromatographic method for the simultaneous determination of captopril and hydrochlorothiazide in human plasma samples was developed. Captopril was derivatized with 2,4'-dibromoacetophenone (pBPB) to form a captopril-pBPB adduct. From acidified serum plasma samples, the hydrochlorothiazide and derivatized captopril was extracted with 5 ml ether, then with 5 ml dichloromethane. Effective chromatographic separation was achieved using a C(18) column (DIAMONSIL 150 mmx4 mm i.d., 5 microm) based on an acetonitrile-trifluoroacetic acid-water gradient elution at a flow rate of 1.2 ml/min. The internal standard (IS), derivatized captopril and hydrochlorothiazide were detected at 263 nm and were eluted at 4.2, 6.8 and 16.9 min, respectively. No endogenous substances were found to interfere. The limit of quantification for hydrochlorothiazide and derivatized captopril in plasma were 3.3 and 7 ng/ml. The calibration curve for derivatized captopril showed linearity in the range 20-4000 ng/ml, with a regression coefficient corresponding to 0.9993 and the coefficient of the variation of the points of the calibration curve being lower than 10%. The calibration curve for hydrochlorothiazide showed linearity in the range 10-1200 ng/ml, with a regression coefficient corresponding to 0.9999 and the coefficient of the variation of the points of the calibration curve being lower than 10%. The method was suitably validated and successfully applied to the determination of captopril and hydrochlorothiazide in human plasma samples.
Collapse
|
|
19 |
82 |
5
|
Abstract
Blood and milk concentrations of captopril, a new antihypertensive agent, were studied in 12 lactating normotensive subjects after the administration of 100 mg captopril tablets on a three times daily regimen for a total of seven doses. Peak blood concentrations (+/- S.E.M.) of captopril after the administration of the seventh 100-mg tablet averaged 713.1 +/- 140.6 ng/ml, as compared to average peak milk concentrations of 4.7 +/- 0.7 ng/ml. Time to peak blood concentrations averaged 1.1 +/- 0.2 hour, while time to peak milk concentrations averaged 3.8 +/- 0.6 hours. The data suggest that the human breast selectively restricts the passage of captopril from blood into milk.
Collapse
|
|
44 |
70 |
6
|
Wilding IR, Davis SS, Bakhshaee M, Stevens HN, Sparrow RA, Brennan J. Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation. Pharm Res 1992; 9:654-7. [PMID: 1608898 DOI: 10.1023/a:1015806211556] [Citation(s) in RCA: 70] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Captopril has been administered to eight healthy male subjects by means of a pulsatile delivery system that was designed to release the drug in the colonic region of the intestine. The gastrointestinal transit and pulsatile release were followed using gamma scintigraphy. A pulsatile capsule system with release after a nominal 5-hr period was found to perform reproducibly in vitro and in vivo. In six of the eight subjects, the drug was delivered to the colon, and in the remaining two subjects, to the terminal ileum. Measurable blood levels of free captopril were found in three subjects. Variable instability of the drug in the distal intestine is suggested as a possible reason for the lack of absorption of the drug in the majority of subjects.
Collapse
|
Clinical Trial |
33 |
70 |
7
|
Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O'Dea RF. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr 1983; 103:799-805. [PMID: 6355421 DOI: 10.1016/s0022-3476(83)80490-9] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
The efficacy and safety of captopril were studied in 10 patients with secondary hypertension (renal parenchymal disease, four patients; renal artery stenosis, two; and renal transplant rejection, four). Captopril was administered according to a dose titration protocol that randomized the initial three doses (0.5, 1.0, and 2.0 mg/kg) of drug to one of six possible sequences. All patients received diuretics prior to and during captopril therapy. A significant reduction in mean blood pressure was observed in all 10 patients during the initial dose titration. No correlation was observed between captopril dose and magnitude of the blood pressure reduction. The onset of antihypertensive action began approximately 15 minutes after each orally administered dose and reached the nadir approximately 1 1/2 hours later. Blood pressure returned to predrug levels between 6 and 10 hours after the dose. A significant reduction in systolic and diastolic blood pressure was noted in all subjects after 1 week of captopril treatment and was maintained during the course of continuous therapy in nine of 10 patients. Captopril combined with hydrochlorothiazide produced a satisfactory therapeutic response in five patients; in four others, additional antihypertensive drugs were required. No significant adverse effects were observed. Plasma renin activity determined prior to initiation of captopril was not predictive of blood pressure response to the drug. The clearance of captopril from patients with kidney failure ranged from 14.1 to 18.8 ml/min/kg in five subjects with creatine clearance between 10 and 21 ml/min/1.73 m2.
Collapse
|
Clinical Trial |
42 |
55 |
8
|
Jarrott B, Anderson A, Hooper R, Louis WJ. High-performance liquid chromatographic analysis of captopril in plasma. J Pharm Sci 1981; 70:665-7. [PMID: 7019414 DOI: 10.1002/jps.2600700622] [Citation(s) in RCA: 54] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A sensitive assay is described for quantitating plasma captopril levels. Captopril is an orally active inhibitor of angiotensin-converting enzyme. Blood from patients taking this drug was collected into tubes containing edetate and ascorbic acid, and the plasma was separated by centrifugation. After addition of an internal standard, the plasma was deproteinized and the supernate was adjusted to pH 6.5 N-(1-Pyrene)-maleimide was added to derivatize captopril and an internal standard to fluorescent adducts. These derivatives then were extracted into ethyl acetate-benzene (1:1) and separated from other derivatized thiols by high-performance liquid chromatography. The sensitivity of the assay was 150 pmoles/ml. Preliminary pharmacokinetics were obtained in patients taking captopril chronically for essential hypertension. After administration of 100 mg of captopril for patients who had fasted overnight, the plasma levels rose rapidly; peak levels were obtained at approximately 37 min. Thereafter, the plasma levels declined rapidly, and the terminal half-life was approximately 40 min. In these patients, the time course of the plasma levels did not reflect changes in blood pressure, so there appeared to be no direct relationship between plasma levels of the parent compound and blood pressure changes.
Collapse
|
|
44 |
54 |
9
|
Wieling J, Hendriks G, Tamminga WJ, Hempenius J, Mensink CK, Oosterhuis B, Jonkman JH. Rational experimental design for bioanalytical methods validation. Illustration using an assay method for total captopril in plasma. J Chromatogr A 1996; 730:381-94. [PMID: 8680594 DOI: 10.1016/0021-9673(96)00006-4] [Citation(s) in RCA: 53] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Generally, bioanalytical chromographic methods are validated according to a predefined programme and distinguish a pre-validation phase, a main validation phase and a follow-up validation phase. In this paper, a rational, total performance evaluation programme for chromatographic methods is presented. The design was developed in particular for the pre-validation and main validation phases. The entire experimental design can be performed within six analytical runs. The first run (pre-validation phase) is used to assess the validity of the expected concentration-response relationship (lack of fit, goodness of fit), to assess specificity of the method and to assess the stability of processed samples in the autosampler for 30 h (benchtop stability). The latter experiment is performed to justify overnight analyses. Following approval of the method after the pre-validation phase, the next five runs (main validation phase) are performed to evaluate method precision and accuracy, recovery, freezing and thawing stability and over-curve control/dilution. The design is nested, i.e., many experimental results are used for the evaluation of several performance characteristics. Analysis of variance (ANOVA) is used for the evaluation of lack of fit and goodness of fit, precision and accuracy, freezing and thawing stability and over-curve control/dilution. Regression analysis is used to evaluate benchtop stability. For over-curve control/dilution, additional to ANOVA, also a paired comparison is applied. As a consequence, the recommended design combines the performance of as few independent validation experiments as possible with modern statistical methods, resulting in optimum use of information. A demonstration of the entire validation programme is given for an HPLC method for the determination of total captopril in human plasma.
Collapse
|
|
29 |
53 |
10
|
Funke PT, Ivashkiv E, Malley MF, Cohen AI. Gas chromatography/selected ion monitoring mass spectrometric determination of captopril in human blood. Anal Chem 1980; 52:1086-9. [PMID: 7008647 DOI: 10.1021/ac50057a021] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
|
45 |
51 |
11
|
Matsuki Y, Fukuhara K, Ito T, Ono H, Ohara N, Yui T, Nambara T. Determination of captopril in biological fluids by gas-liquid chromatography. J Chromatogr A 1980; 188:177-83. [PMID: 6991514 DOI: 10.1016/s0021-9673(00)88428-9] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
The quantitation of captopril in biological fluids by gas-liquid chromatography using a flame photometric detector is described. Captopril was converted into an adduct with N-ethylmaleimide and then into the hexafluoroisopropyl ester. The latter derivative was separated on a 2% OV-210 column and determined by employing the captopril-N-hexylmaleimide adduct as an internal standard. The blood level and urinary excretion of captopril administered intravenously to dogs were measured by the proposed method.
Collapse
|
|
45 |
48 |
12
|
Shimada K, Tanaka M, Nambara T, Imai Y, Abe K, Yoshinaga K. Determination of captopril in human blood by high-performance liquid chromatography with electrochemical detection. JOURNAL OF CHROMATOGRAPHY 1982; 227:445-51. [PMID: 7037807 DOI: 10.1016/s0378-4347(00)80397-7] [Citation(s) in RCA: 48] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
A new method for quantitation of captopril in human blood is described. Captopril was derivatized with N-(4-dimethylaminophenyl)maleimide into the electrochemically active adduct. The derivative was separated and determined by high-performance liquid chromatography with an electrochemical detector on a reversed-phase column. The proposed method was satisfactory for determination of captopril in whole blood with respect to accuracy and precision. The detection limit of captopril thereby obtained was 10 ng/ml. The blood levels of captopril in patients orally given an official dose were measured by the present method.
Collapse
|
|
43 |
48 |
13
|
Wong KK, Lan S, Migdalof BH. In vitro biotransformations of [14C]captopril in the blood of rats, dogs and humans. Biochem Pharmacol 1981; 30:2643-50. [PMID: 7028042 DOI: 10.1016/0006-2952(81)90532-3] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
|
44 |
46 |
14
|
Duchin KL, Pierides AM, Heald A, Singhvi SM, Rommel AJ. Elimination kinetics of captopril in patients with renal failure. Kidney Int 1984; 25:942-7. [PMID: 6381858 DOI: 10.1038/ki.1984.114] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Captopril kinetics were determined after a 100-mg oral dose of 14C-captopril in 21 patients with various degrees of renal impairment. Elimination kinetics of captopril were evaluated by model-independent methods. The body clearance (ClB) of captopril decreased steadily with decreasing creatinine clearance (ClCr) from 5.2 ml/min/kg for mild renal failure patients to 1.6 ml/min/kg for hemodialysis patients during an interdialytic period. In patients with mild renal impairment, renal and nonrenal clearances of captopril averaged 2.2 and 3.0 ml/min/kg, respectively, and fell (P less than 0.001) to 0.2 and 1.5 ml/min/kg in patients with severe renal impairment. There were no significant differences in the extent of total cumulative excretion (fecal plus urinary) of radioactivity over a 96- to 120-hr period between the patients with mild, moderate, and severe renal impairment. The 48-hr renal excretion of captopril averaged 29, 21, and 8% of the dose in the mild, moderate, and severe renally impaired groups. In five additional hemodialysis patients, the mean dialyzer clearance of captopril averaged 120 ml/min. Approximately 35% of the dose was recovered in the 4-hr dialysate. Based on the above findings, a reduction in the dose of captopril is necessary in patients with renal failure.
Collapse
|
|
41 |
43 |
15
|
Kok RJ, Visser J, Moolenaar F, de Zeeuw D, Meijer DK. Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 1997; 693:181-9. [PMID: 9200533 DOI: 10.1016/s0378-4347(97)00002-9] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
This study describes the development and comparison of two HPLC methods for the analysis of the antihypertensive drug captopril. The first method is based on a precolumn derivatization of captopril with the fluorescent label monobromobimane (MBB). The second method is based on a postcolumn reaction with the fluorescent reagent o-phthaldialdehyde (OPA). Since the disulfide metabolites of captopril can be reconverted to the active drug in vivo, the bioanalysis of captopril should involve both the determination of its free thiol form (free captopril) and the total amount of free thiol and reducible disulfides (total captopril). For total captopril analysis, disulfides were reduced with tributylphosphine (TBP) prior to protein precipitation. Since the reducing agent interfered with the MBB derivatization reaction, this method was not suitable for total captopril analysis. Both methods were validated for the bioanalysis of free captopril in human plasma. After removal of plasma proteins, samples were analyzed without an additional extraction procedure. The limit of quantitation in plasma was 12.5 ng/ml for the MBB method (limit of detection 30 pg) and 25 ng/ml for the OPA method (limit of detection 50 pg). The OPA method was also validated for total captopril analysis in human plasma and urine. The limit of quantitation was 25 ng/ml in plasma and 250 ng/ml in urine (limit of detection 50 pg). We conclude that for the analysis of free captopril the precolumn MBB method is superior to the OPA method since only the derivatization reaction has to be carried out immediately. The postcolumn OPA method is especially suitable for the analysis of total captopril since reducing reagents and high concentrations of endogenous thiols do not interfere with the derivatization reaction.
Collapse
|
|
28 |
42 |
16
|
Sypniewski S, Bald E. Determination of captopril and its disulphides in whole human blood and urine by high-performance liquid chromatography with ultraviolet detection and precolumn derivatization. J Chromatogr A 1996; 729:335-40. [PMID: 9004958 DOI: 10.1016/0021-9673(95)01124-2] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
An assay that measures the total, and protein-bound captopril, the orally active antihypertensive drug, in whole human blood and urine has been developed. The procedure involves a precolumn derivatization of the drug via its sulfhydryl group with 1-benzyl-2-chloropyridinium bromide followed by solid-phase extraction and reversed-phase high-performance liquid chromatography separation with ultraviolet detection at 314 nm. Oxidized and protein-bound captopril is converted to reduced form by the use of triphenylphosphine and derivatized and quantified in the same manner. The proposed method offers the possibility of determining the in vivo redox status of captopril in blood of patients orally given a standard dose of at least 12.5 mg of captopril as part of the treatment of hypertensive disease and/or congestive heart failure. In the recommended procedure the sulfhydryl form of captopril is trapped with minimal oxidation by derivatizing blood samples at the time of collection. This is attained by drawing blood directly into tubes containing solutions of 1-benzyl-2-chloropyridinium bromide. The method enables also the determination of urinary excretion of captopril and its disulphides after oral administration of the drug. Accurate determinations are possible over a concentration range of 10 to 500 ng/ml captopril in blood, 50 to 1200 ng/ml captopril in urine and 10 to 1000 ng/ml captopril disulphide and 50 to 3000 ng/ml captopril disulphide in blood and urine, respectively. The detection and quantification limits for both blood and urine are 0.3 and 10 ng/ml, respectively.
Collapse
|
Clinical Trial |
29 |
41 |
17
|
Hayashi K, Miyamoto M, Sekine Y. Determination of captopril and its mixed disulphides in plasma and urine by high-performance liquid chromatography. JOURNAL OF CHROMATOGRAPHY 1985; 338:161-9. [PMID: 3894398 DOI: 10.1016/0378-4347(85)80080-3] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
A high-performance liquid chromatographic method has been developed which enables sensitive determination of captopril and its mixed disulphides in plasma and urine after oral administration of a new antihypertensive agent, 1-(D-3-acetylthio-2-methylpropanoyl)-L-prolyl-L-phenylalanine (DU-1219, I). Captopril is derivatized with a new reagent, N-(4-benzoylphenyl)maleimide and the derivative is extracted with chloroform and assayed using a liquid chromatograph equipped with an ultraviolet detector at 254 nm. Mixed disulphides of captopril with thiol compounds such as cysteine, glutathione and plasma proteins are reduced with tributylphosphine to form captopril, followed by derivatization with N-(4-benzoylphenyl)maleimide. Accurate determinations are possible over a concentration range of 10-500 ng/ml captopril in plasma, and 100-2500 ng/ml captopril in urine. The coefficients of variation of captopril in plasma (200 ng/ml) and urine (500 ng/ml) are 3.7% and 2.6%, respectively, and those of mixed disulphides of captopril are similar to those of captopril. Plasma levels and urinary excretion of captopril and its mixed disulphides in healthy volunteers following single oral administration of I (50 mg) have also been determined.
Collapse
|
|
40 |
39 |
18
|
Onoyama K, Hirakata H, Iseki K, Fujimi S, Omae T, Kobayashi M, Kawahara Y. Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. Hypertension 1981; 3:456-9. [PMID: 7030952 DOI: 10.1161/01.hyp.3.4.456] [Citation(s) in RCA: 39] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Blood concentration and urinary excretion of captopril following 50 mg oral administration were determined by high-performance liquid chromatography in normal subjects and patients with chronic renal failure. In normal subjects, the maximum blood concentration of the free form of captopril was obtained within 1 hour and was not detectable after 6 hours; 41% of administered captopril was excreted into the urine as free form and metabolites within 2 hours, and 58% within 6 hours. In chronic renal failure patients with an average serum creatinine of 5.1 mg/dl, the absorption constant (Ka), maximum concentration (Cmax), and area under the blood concentration curve (AUC) were not significantly different from those in the normal subjects, but the elimination constant (Ke) and biological half-life (T1/2) showed a significant delay in the disappearance of captopril from the blood (p less than 0.01 respectively). The cumulative amount of urinary excretion of either free-form captopril or its' metabolites was significantly decreased at 2, 4, and 6 hours in chronic renal failure patients (p less than 0.01 or less, respectively). Impairment of kidney function is suggested to be an important factor in the promotion of blood retention of captopril.
Collapse
|
|
44 |
39 |
19
|
Amini M, Zarghi A, Vatanpour H. Sensitive high-performance liquid chromatographic method for determination of captopril in plasma. PHARMACEUTICA ACTA HELVETIAE 1999; 73:303-6. [PMID: 10443174 DOI: 10.1016/s0031-6865(99)00007-2] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
A rapid, simple and sensitive high-performance liquid chromatographic method for the determination of captopril in plasma has been developed. Captopril is derivatized with a new reagent, 2-bromo-2'-acetonaphthone to form a product that showed ultraviolet-absorbing properties. For plasma samples, the protein was removed with 6% perchloric acid and the derivatized captopril was extracted with diethyl ether. The chromatographic separation was performed on an analytical mu bondapak NH2 column (300 x 3.9 mm, i.d.) with an isocratic mobile phase consisting of n-hexane-2-propanol-methanol-acetic acid (68:15:15:2). Using ultraviolet detection at 246 nm, the quantification limit for captopril in plasma was 10 ng/ml. The calibration curve was linear over the concentration range 12.5-500 ng/ml. The average recovery was 95% for plasma. The inter-day and intra-day assay coefficients of variation were found to be less than 12%.
Collapse
|
|
26 |
38 |
20
|
Ohman KP, Kågedal B, Larsson R, Karlberg BE. Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. J Cardiovasc Pharmacol 1985; 7 Suppl 1:S20-4. [PMID: 2580171 DOI: 10.1097/00005344-198507001-00005] [Citation(s) in RCA: 37] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Nine patients with essential hypertension treated with bendroflumethiazide were given captopril 25 mg orally on three occasions to study the pharmacokinetics and blood pressure effects. Study 1: acute and fasting; study 2 and 3: with and without concomitant food intake (randomized order) after chronic treatment with captopril 25 mg three times a day for 4-5 weeks. Total and non-protein-bound captopril were measured by high performance liquid chromatography. Baseline mean arterial pressure (MAP) was lower during chronic treatment. MAP reduction was slightly more pronounced initially with concomitant food intake but thereafter the reductions were similar for up to 12 h in the three studies. Mean values for maximal MAP reductions and peak plasma concentrations of captopril occurred at the same time, but individual values were not correlated with each other. Peak plasma concentrations and area under the curve (AUC) of total and non-protein-bound captopril were slightly reduced with concomitant food intake. Chronic treatment did not consistently change the kinetics except for a slight prolongation of terminal half-life of non-protein-bound captopril. The AUC was higher during the chronic studies, probably owing to the baseline presence of captopril in plasma. It appears that captopril can be given twice daily and together with food without loss of blood pressure control in essential hypertension.
Collapse
|
Clinical Trial |
40 |
37 |
21
|
Richer C, Giroux B, Plouin PF, Maarek B, Giudicelli JF. Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. Br J Clin Pharmacol 1984; 17:243-50. [PMID: 6324834 PMCID: PMC1463370 DOI: 10.1111/j.1365-2125.1984.tb02338.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
The kinetics of captopril plasma levels and of the drug-induced plasma converting enzyme activity (PCEA), plasma renin activity (PRA) and diastolic blood pressure (DBP) modifications were studied over 24 h after oral administration of captopril, 1 mg/kg, to ten hypertensive patients. Free unchanged captopril pharmacokinetic parameters were: t1/2, alpha: 0.45 +/- 0.06 h; tmax: 0.98 +/- 0.13 h; Cmax: 1.31 +/- 0.20 mg l-1; t1/2,z: 0.66 +/- 0.13 h; V: 0.614 +/- 0.104 1 kg-1 and CLtot: 0.690 +/- 0.082 l h-1 kg-1. At 6 h captopril was no longer detectable in plasma. The onset of PCEA inhibition and of DBP decrease closely followed the rise of captopril's plasma levels, while that of PRA increase was delayed. In contrast, while captopril rapidly disappeared from plasma, its biological and antihypertensive effects were long-lasting. The lack of correlation between the relative bioavailability of captopril and the induced reduction in DBP (evaluated by the corresponding AUCs) suggests that free unchanged captopril plasma monitoring is not an adequate indicator of hypertensive patients' potential responsiveness to captopril's blood pressure lowering effects.
Collapse
|
research-article |
41 |
37 |
22
|
Franklin ME, Addison RS, Baker PV, Hooper WD. Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography--mass spectrometry and its application to pharmacokinetic studies. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL SCIENCES AND APPLICATIONS 1998; 705:47-54. [PMID: 9498669 DOI: 10.1016/s0378-4347(97)00481-7] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
An enhanced, sensitive GC-MS assay is presented for the highly specific angiotensin-converting enzyme (ACE) inhibitor, captopril. This method improves previously published assays by using solid NEM as stabilizer in the collection tubes, a rapid extraction technique with dichloromethane and back-extraction into base, a commercially available internal standard (thiosalicylic acid) and a capillary GC column. Captopril and the internal standard are measured as their bis-pentafluorobenzyl derivatives. The assay was linear from 10 to 5000 ng/ml with a mean recovery following solvent extraction at 50, 200 and 1000 ng/ml of 77%. At mean values of 45.9, 187 and 980 ng/ml inter-assay precision and accuracy were 4.0, 2.9 and 3.5% and 8.2, 6.5 and 3.1%, respectively. Analysis of captopril concentrations in plasma samples from 20 volunteers following oral administration of 100 mg of captopril provided the following pharmacokinetic data (mean+/-S.D.): Cmax, 1470+/-467 ng/ml; AUC(0-infinity), 1736+/-481 ng/ml.h; Tmax, 0.73 h; k(e), 0.468+/-0.122 h(-1); elimination half life, 1.58/-0.41 h.
Collapse
|
|
27 |
35 |
23
|
Aykin N, Neal R, Yusof M, Ercal N. Determination of captopril in biological samples by high-performance liquid chromatography with ThioGlo 3 derivatization. Biomed Chromatogr 2001; 15:427-32. [PMID: 11746237 DOI: 10.1002/bmc.95] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Captopril, a well-known angiotensin converting enzyme (ACE) inhibitor, is widely used for treatment of arterial hypertension. Recent studies suggest that it may also act as a scavenger of free radicals because of its thiol group. Therefore, the present study describes a rapid, sensitive and relatively simple method for the detection of captopril in biological tissues with reverse-phase HPLC. Captopril was first derivatized with ThioGlo 3 [3H-Naphto[2,1-b]pyran,9-acetoxy-2-(4-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)phenyl-3-oxo-)]. It was then detected by fluorescence-HPLC using an Astec C(18) column as the stationary phase and a water:acetonitrile:acetic acid:phosphoric acid mixture (50:50; 1 mL/L acids) as the mobile phase (excitation wavelength, 365 nm; emission wavelength, 445 nm). The calibration curve for captopril was linear over a range of 10-2500 nM and the coefficient of variation acquired for the within- and between-run precision for captopril was 0.5 and 3.8%, respectively. The detection limit of captopril with this method was found to be 200 fmol/20 microL injection volume. Its relative recovery from biological samples was determined to the range from 93.3 to 105.3%. Based on these results, we believe that our method is advantageous for captopril determination.
Collapse
|
|
24 |
34 |
24
|
Bald E, Sypniewski S, Drzewoski J, Stepień M. Application of 2-halopyridinium salts as ultraviolet derivatization reagents and solid-phase extraction for determination of captopril in human plasma by high-performance liquid chromatography. JOURNAL OF CHROMATOGRAPHY. B, BIOMEDICAL APPLICATIONS 1996; 681:283-9. [PMID: 8811438 DOI: 10.1016/0378-4347(95)00565-x] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
A high-performance liquid chromatographic method was developed for the determination of captopril in human plasma. 1-Benzyl-2-chloropyridinium bromide (BCPB) was used as a precolumn derivatizing reagent. The mercapto group of captopril was arylated by the reagent to generate a stable UV-sensitive product. The derivative was solid-phase extracted (SPE), separated on a C18 column using reversed-phase ion-paring chromatography and monitored by a spectrophotometric detector at 314 nm. The method enabled sensitive determination of captopril and its disulphides in human plasma in patients after oral administration. Disulphides of captopril with captopril itself and with endogenous thiol compounds are reduced with triphenylphosphine to form captopril, followed by derivatization with the same reagent. The quantification limit was 10 ng/ml. Calibration curves were prepared for human plasma samples spiked with captopril and captopril disulphide. The calibration curves were linear in the range of 10 to 500 ng/ml for captopril and 10 to 1000 ng/ml for captopril disulphide.
Collapse
|
|
29 |
34 |
25
|
Leis HJ, Leis M, Welz W, Malle E. Determination of captopril in human blood by gas chromatography-negative-ion chemical ionization mass spectrometry with [18O4]captopril as internal standard. JOURNAL OF CHROMATOGRAPHY 1990; 529:299-308. [PMID: 2229249 DOI: 10.1016/s0378-4347(00)83836-0] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
A method for the quantitative measurement of captopril in human blood is described. Blood was immediately treated with N-ethylmaleimide to prevent oxidative degradation. The carboxyl moiety was derivatized to the pentafluorobenzyl ester, which shows excellent properties for negative-ion chemical ionization mass spectrometry. A stable isotope-labelled standard was prepared from the intact target molecule in quantitative yield by exchanging the oxygen atoms of the free carboxylic acid and the imide moiety against 18O. The detection limit under negative-ion chemical ionization conditions is ca. 100 times lower than under electron-impact or positive-ion chemical ionization conditions, therefore only very small amounts of the original sample have to be analysed. The method was applied to be quantitative determination of unchanged captopril in human plasma after oral administration of a 25-mg dose.
Collapse
|
|
35 |
34 |